Cure8 research brief
People with IBD often hear about “treat-to-target” as a path to deeper healing.
This review explains that while targets have broadened beyond symptoms to include endoscopy and molecular goals, the evidence that systematic monitoring and protocolized treatment changes improve outcomes is still uncertain for many patients.
It matters because decisions about intensified monitoring or changing therapy when you feel well but tests show inflammation should be individualized until ongoing trials provide clearer answers.
Clinicians managing IBD, researchers studying treat-to-target strategies and biomarkers, and patients (and caregivers) considering monitoring intensity or proactive treatment changes.
This review summarizes the changing goals used to define success in IBD care and questions how well the second part of T2T—regular monitoring plus prespecified treatment escalation—has been proven.
It notes that deeper targets (endoscopic, histologic, transmural, molecular) are increasingly proposed because observational data link them to better long-term outcomes, but emphasizes that trials testing whether proactively changing therapy based on monitoring improve results have been inconsistent.
Clinically, the paper proposes an individualized framework for applying T2T that considers disease history, inflammatory trajectory, available therapies, and patient preferences rather than a one-size-fits-all mandate.
It also flags practical barriers to implementation such as inconsistent monitoring in routine practice and uncertainty about benefits for asymptomatic patients with residual inflammation.
This is a review/critical appraisal (abstract-level content provided). It summarizes existing evidence and ongoing trials but does not present new trial results. QUOTIENT, VERDICT, and VECTORS are mentioned as ongoing studies that may provide stronger trial evidence in future.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...
The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.
If you or someone you care for is not responding to anti‑TNF drugs for ulcerative colitis, this review explains biological reasons why that may happen and points toward research directions that could lead to better tests...
